HCA Healthcare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCA research report →
Range $369 – $579
Price Chart
About the company
HCA Healthcare, Inc. , operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services.
- CEO
- Samuel N. Hazen
- IPO
- 2011
- Employees
- 320,000
- HQ
- Nashville, TN, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend, trading above both the 50-day and 200-day moving averages. It sits much closer to its 52-week high than its low, which keeps the secular setup constructive even after a sharp run.
Street sentiment stays constructive: the consensus is Buy with a $466.26 target, while the median target is $485. Recent updates skew higher, with multiple firms lifting targets into the $486-$500 range even as most ratings stayed unchanged.
HCA has a clean beat streak, with 8 straight EPS beats and the latest quarter topping estimates by 7.1%. Next-year EPS is still trending higher to 31.2881, so shareholders should watch whether management can keep margin discipline and convert steady revenue growth into another beat.
The pattern leans to net selling, but most of the activity is award, vesting, or other non-discretionary flows rather than pure open-market conviction. The only clear discretionary sale in the period was 3,500 shares by SVP and Chief Nurse Executive Erica Rossitto, alongside a smaller sale by EVP Michael Schlosser.
Profitability remains solid, with a 15.31% operating margin and 8.61% net margin on 3.6% revenue growth. Cash generation is strong at $12.636 billion of operating cash flow and $17.58 billion of free cash flow, but leverage is heavy with $48.697 billion of total debt against $1.04 billion of cash.
HCA screens as a premium large-cap health care facilities operator, supported by a 16.47 P/E and a market cap near $99.6 billion. The setup favors a quality multiple versus the sector, though the debt load keeps valuation discipline important.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $99.34B
- P/E
- 15.76
- Fwd P/E
- 15.77
- PEG
- 1.01
- P/S
- 1.27
- P/B
- -13.12
- EV/EBITDA
- 9.51
- Div Yield
- 0.64%
- Gross Margin
- 21.69%
- Op Margin
- 15.34%
- Net Margin
- 8.61%
- ROE
- -100.45%
- ROIC
- 18.52%
Latest fiscal year · YoY change
- Revenue
- $75.60B+7.1%
- Gross Profit
- $31.37B+9.4%
- Op Income
- $11.96B
- Net Income
- $6.78B+17.8%
- EPS
- $28.70+28.9%
- OCF Growth
- +20.2%
- FCF Growth
- +36.4%
- 52W High
- $556.52
- 52W Low
- $353.99
- 50D MA
- $458.76
- 200D MA
- $445.18
- Beta
- 1.11
- RSI (14)
- 50
- Avg Volume
- 1.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
HCA Healthcare said third-quarter results improved across volumes, pricing, and costs, and it expects 2026 to finish in the upper half of its guidance range while signaling 2027 earnings will be generally consistent with 2026.· October 27, 2026
- Same-facility adjusted admissions rose 3% year over year, marking the 22nd consecutive quarter of volume growth.
- Exchange volume remained a major headwind: exchange equivalent admissions fell about 19%, and management estimated a roughly $400 million adjusted EBITDA impact from payer mix shifts in the quarter.
- Pricing and cost trends improved, with insured revenue per adjusted admission rising faster than in the first half and same-facility cost per equivalent admission essentially flat year over year ex supplemental payments.
- HCA recognized about $50 million of incremental net Medicaid supplemental payment benefit in Q3 and now expects full-year 2026 incremental net benefit of $600 million to $800 million.
- Management said 2027 earnings should be generally consistent with 2026, helped by 2% to 3% volume growth and cost savings, but offset by a $550 million to $650 million drop in Medicaid supplemental payment benefits from 2026-related grandfathered programs.
Third-quarter same-facility admissions increased 2.7%, equivalent admissions increased 3%, and ER visits increased 5.1%; Medicare adjusted admissions rose 3.2%, Medicaid rose 2.7%, commercial excluding exchanges rose 2.7%, and exchange equivalent admissions fell about 19% year over year. HCA said diluted EPS as adjusted increased almost 4%, and revenue per adjusted admission for the insured business excluding supplemental payments increased at a higher rate than in the first half. The company said same-facility cost per equivalent admission excluding Medicaid supplemental payment programs was essentially flat versus last year and improved 40 basis points sequentially. It generated approximately $4.5 billion of operating cash flow, spent about $1.36 billion on capital expenditures, repurchased approximately $3 billion of stock, and paid $165 million in dividends. For full-year 2026, management reaffirmed guidance and said it expects to finish in the upper half of its ranges; it also raised expected incremental net benefit from Medicaid supplemental payment programs to $600 million to $800 million for 2026. Looking ahead to 2027, management preliminarily expects volume growth of 2% to 3%, about $550 million to $650 million less in Medicaid supplemental payment net benefits, favorable cost performance from resiliency efforts and operating leverage, and earnings generally consistent with 2026.
Samuel Hazen framed the quarter as evidence of improving execution, with stronger demand, better insured revenue trends, and improved cost performance. He emphasized HCA’s scale, diversification, and resiliency programs as the foundation for navigating policy changes, saying the company believes it is positioned to end the year positively and remain on track for its long-term objectives. For 2027, he stressed that the planning process is still early, but he sees strong underlying demand, continued value from digital transformation and network development, and ongoing benefits from enterprise-wide resiliency.
Michael Marks highlighted the main financial drivers: volume growth, payer mix pressure from exchanges, supplemental payment benefits, and cost discipline. He quantified the exchange headwind at roughly $400 million in Q3 adjusted EBITDA and said uninsured volume reached about 10.5% of total equivalent admissions versus 8.5% a year ago. On capital allocation, he cited about $1.36 billion of capex, $3 billion of share repurchases, $165 million of dividends, and $4.5 billion of operating cash flow, while noting leverage remains in the lower half of the target range and the balance sheet is strong. He also said same-facility cost per equivalent admission excluding supplemental payments was flat year over year and down 40 basis points sequentially, and that professional fees remain a pressure point, up about 12% year over year.
Analysts focused on how HCA is bridging from 2026 to 2027, especially the size of exchange and Medicaid supplemental payment headwinds versus resiliency savings. Management declined to size the exchange headwind or 2027 cost savings precisely, saying they will wait for fourth-quarter data and enrollment visibility before giving more detailed guidance in January. Questions also covered 340B, elective surgery trends, the inpatient-only list, and HR1; management said the proposed 340B rule would be positive if finalized, elective surgery is still under pressure from coverage and affordability issues, and work requirements in expansion states could have a modest 2027 impact. On the supplemental payment question, management clarified that the 2027 step-down is mostly tied to grandfathered, prior-year-related payments, with Florida the largest component and Virginia and other states contributing as well.
The call showed improving operating momentum: volumes grew, insured pricing improved, and costs were well controlled despite payer mix pressure. Management sounded confident that resiliency, digital transformation, and network investments can continue to offset headwinds and support growth beyond 2026. HCA also pointed to a strong balance sheet, active capital returns, and a favorable view of the proposed 340B rule.
The biggest risks remain exchange-related payer mix deterioration, lower Medicaid supplemental payment benefits in 2027, and continued pressure on elective/surgical volumes. Management repeatedly said the policy environment is still fluid and that 2027 guidance is too early to size precisely. Professional fees were also called out as a persistent cost pressure, and management said affordability and coverage issues are still weighing on elective care.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 66.8%
- Shares Outstanding
- 208.89M
- Float Shares
- 139.59M
of shares held by institutions
1,408 13F filers
Buy/sell ratio 0.38. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HCA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Jun 17, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Jun 17, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 27, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 19, 25 | Filing → |
| Val HoyleHouse · OR04 | Sell | Dec 27, 24 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | May 15, 25 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | May 15, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 14.72M | ▼ 178.50K |
| Blackrock, Inc. | 12.43M | ▼ 573.78K |
| Vanguard Capital Management LLC | 9.42M | ▼ 720.22K |
| Sanders Capital, LLC | 8.79M | ▼ 36.51K |
| State Street Corp | 6.99M | ▼ 477.96K |
| Wellington Management Group Llp | 4.30M | ▼ 404.73K |
| Geode Capital Management, LLC | 3.51M | ▼ 161.63K |
| First Eagle Investment Management, LLC | 3.27M | ▼ 28.85K |
| Morgan Stanley | 2.64M | ▲ 49.13K |
| Vanguard Portfolio Management LLC | 2.56M | ▼ 157.03K |
| Capital World Investors | 2.55M | ▲ 576.05K |
| Jpmorgan Chase & Co | 2.25M | ▼ 38.71K |
Held by 1,860 ETFs
Biggest fund positions in HCA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Schlosser Michael J | other | 1,273 |
| Nov 13, 26 | Schlosser Michael J | other | 1,273 |
| Nov 6, 26 | Rossitto Erica | other | 5,040 |
| Nov 6, 26 | Rossitto Erica | other | 8,080 |
| Nov 6, 26 | Rossitto Erica | other | 6,601 |
| Nov 10, 26 | Rossitto Erica | sell | 3,500 |
| Nov 6, 26 | Rossitto Erica | other | 5,040 |
| Nov 6, 26 | Rossitto Erica | other | 8,080 |
| Nov 4, 26 | Elcan Patricia F | other | 886,871 |
| Nov 4, 26 | Elcan Patricia F | other | 886,871 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HCA coverage
Recent articles, reports, and earnings notes.

HCA Healthcare (HCA): Growth vs. Leverage Pressure
HCA Healthcare posted solid revenue and EPS growth, but its highly leveraged balance sheet and payer-mix headwinds keep the stock at Hold. The report sees durable demand and outpatient expansion offset by exchange coverage losses and balance sheet risk.

Medtech's selloff is a payer-mix warning, not a demand collapse
The setbacks at Intuitive Surgical and HCA expose real pressure in elective procedures, but the evidence points more to coverage and payer mix than a broad healthcare demand collapse. UnitedHealth's guidance increase and Intuitive's maintained procedure outlook show why investors should separate marginal-patient exposure from underlying utilization.

HCA Healthcare (HCA): Scale, Cash Flow, and Leverage
HCA Healthcare delivered strong revenue, earnings, and cash flow growth despite a choppy quarter. The stock looks attractively valued, but its heavy debt load keeps the risk profile elevated.
Want a deeper read on HCA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why HCA Healthcare (HCA) is a Strong Growth Stock
zacks.com · Nov 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. - HCA
prnewswire.com · Nov 19
HCA Healthcare Collects Record-Breaking 21,857 Pounds of Medication During Eighth Annual “Crush the Crisis”
businesswire.com · Nov 19
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. – HCA
globenewswire.com · Nov 17
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
zacks.com · Nov 17
HCA Healthcare, Inc. $HCA Stock Sold by Commonwealth Equity Services LLC
defenseworld.net · Nov 17
Why HCA Healthcare (HCA) is a Top Momentum Stock for the Long-Term
zacks.com · Nov 16
HCA Healthcare, Inc. $HCA Stock: Fifth Third Bancorp Decreases Stake
defenseworld.net · Nov 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice